Overview

Checkpoint Inhibitors Market is forecasted to register a CAGR of 16% from the forecast period 2022-2028.

A checkpoint inhibitor is a medication that disables the proteins that the body's immune system uses to prevent the cancer cells from being destroyed. A type of medication known as a checkpoint inhibitor is used in immunotherapy to help block the proteins found on tumour cells that interfere with the immune system's ability to fight disease. T-cells are one type of immune cell that actively combats cancerous cells. T cells include proteins that either activate or suppress the immune system, depending on the protein. Checkpoints are what they are called. T-cells can activate or deactivate depending on the checkpoint they are at. The switch off checkpoints limit the immune responses' potency and occasionally even prevent the T cells from destroying the cancer cells when cancer cells produce large amounts of proteins. The T-cells can attack the cancer cells when the checkpoint inhibitor prevents the checkpoints from binding with their companion proteins. Checkpoint inhibitors primarily consist of PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, chimeric antigen receptor T-cell, and other medication types. Anticancer checkpoint drugs such as PD-1 and PD-L1 inhibitors prevent the immune checkpoint proteins PD-1 and PDL1 from acting on cell surfaces. It is used to treat cancers of the lung, kidney, blood, bladder, melanoma, and other organs, and it is employed in a variety of industries, including hospitals, retail pharmacies, and internet pharmacies. During the projected period, the market for checkpoint inhibitors is predicted to expand due to the increase in cancer cases worldwide. Due to the rise in demand for effective cancer therapeutics, favourable reimbursement policies offered by manufacturers and insurance providers in some nations, and the increased prevalence of cancer worldwide, checkpoint inhibitors are predicted to experience significant market growth during the forecast period.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Checkpoint Inhibitors Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the study conducted by FutureWise research analysts, the Checkpoint Inhibitors Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Checkpoint Inhibitors Market are :   
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline Plc
• F. Hoffmann-La Roche
• Sanofi
• Merck & Co., Inc.
• BeiGene Ltd
• Shanghai Jhunsi Biosciences Ltd.
• Incyte Corporation
(Note: The list of the major players will be updated with the latest market scenario and trends)

Checkpoint Inhibitors Market Segmentation:
By Drug Class
• PD-1 (Programmed Cell Death Protein 1)
• PD-Ll(Prograrnmed Death-ligand 1)
• CTLA-4 (Cytotoxic Lymphocyte-associated Antigen)
By Therapeutic Application
• Lung Cancer
• Melanoma
• Squarnous Cell Carcinoma
• Urothelial Carcinoma
• Blood Cancer
• Other Therapeutic Applications
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Checkpoint Inhibitors Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Checkpoint Inhibitors Market By Drug Class, By Therapeutic Application, By Distribution Channel and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Checkpoint Inhibitors Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Checkpoint Inhibitors Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Checkpoint Inhibitors Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Checkpoint Inhibitors Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. PD-1 (Programmed Cell Death Protein 1)
   7.2. PD-Ll(Prograrnmed Death-ligand 1)
   7.3. CTLA-4 (Cytotoxic Lymphocyte-associated Antigen)

8. Checkpoint Inhibitors Market, By Therapeutic Application Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Lung Cancer
   8.2. Melanoma
   8.3. Squarnous Cell Carcinoma
   8.4. Urothelial Carcinoma
   8.5. Blood Cancer
   8.6. Other Therapeutic Applications

9. Checkpoint Inhibitors Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospital Pharmacies
   9.2. Retail Pharmacies

10. North America Checkpoint Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Checkpoint Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Checkpoint Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Checkpoint Inhibitors Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   16.1. AstraZeneca PLC
         16.1.1. Company Overview
         16.1.2. Product Portfolio
         16.1.3. SWOT Analysis
         16.1.4. Financial Overview
         16.1.5. Strategic Overview
   16.2. Bristol-Myers Squibb Company
         16.2.1. Company Overview
         16.2.2. Product Portfolio
         16.2.3. SWOT Analysis
         16.2.4. Financial Overview
         16.2.5. Strategic Overview
   16.3. Eli Lilly and Company
         16.3.1. Company Overview
         16.3.2. Product Portfolio
         16.3.3. SWOT Analysis
         16.3.4. Financial Overview
         16.3.5. Strategic Overview
   16.4. GlaxoSmithKline Plc
         16.4.1. Company Overview
         16.4.2. Product Portfolio
         16.4.3. SWOT Analysis
         16.4.4. Financial Overview
         16.4.5. Strategic Overview
   16.5. F. Hoffmann-La Roche
         16.5.1. Company Overview
         16.5.2. Product Portfolio
         16.5.3. SWOT Analysis
         16.5.4. Financial Overview
         16.5.5. Strategic Overview
   16.6. Sanofi
         16.6.1. Company Overview
         16.6.2. Product Portfolio
         16.6.3. SWOT Analysis
         16.6.4. Financial Overview
         16.6.5. Strategic Overview      
   16.7. Merck & Co., Inc.
         16.7.1. Company Overview
         16.7.2. Product Portfolio
         16.7.3. SWOT Analysis
         16.7.4. Financial Overview
         16.7.5. Strategic Overview
   16.8. BeiGene Ltd
         16.8.1. Company Overview
         16.8.2. Product Portfolio
         16.8.3. SWOT Analysis
         16.8.4. Financial Overview
         16.8.5. Strategic Overview
   16.9. Shanghai Jhunsi Biosciences Ltd.
         16.9.1. Company Overview
         16.9.2. Product Portfolio
         16.9.3. SWOT Analysis
         16.9.4. Financial Overview
         16.9.5. Strategic Overview
   16.10.Incyte Corporation
         16.10.1. Company Overview
         16.10.2. Product Portfolio
         16.10.3. SWOT Analysis
         16.10.4. Financial Overview
         16.10.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures